Van Hoeck Koen J, Bael An, Van Dessel Els, Van Renthergem Debbie, Bernaerts Kim, Vandermaelen Veronique, Lax Hildegard, Hirche Herbert, van Gool Jan D
Department of Pediatrics, University Hospital Antwerp, Antwerp, Belgium.
J Urol. 2007 Nov;178(5):2132-6. doi: 10.1016/j.juro.2007.07.051. Epub 2007 Sep 17.
We assessed prospectively the efficacy of holding exercises and/or antimuscarinics (oxybutynin chloride and placebo) for increasing maximum voided volume in prepubertal children with monosymptomatic nocturnal enuresis.
We randomly allocated 149 children to 5 groups, namely holding exercises with placebo (group A), holding exercises with oxybutynin (group B), placebo alone (group C), oxybutynin alone (group D) and alarm treatment (controls, group E). Maximum voided volume was the greatest voided volume from a 48-hour bladder diary, and holding exercise volume was the greatest volume produced with postponement of voiding after a fluid load, once daily for 4 days. Study medication, holding exercise procedures and alarm treatment were administered for 12 weeks.
Holding exercises combined with placebo or oxybutynin significantly increased holding exercise volume and maximum voided volume, by 25% (p <0.001) and 21% (p <0.01), respectively, in group A, and by 43% (p <0.001) and 41% (p <0.001), respectively, in group B. Medication without holding exercises (groups C and D) did not increase holding exercise volume or maximum voided volume, and in these groups oxybutynin was not significantly superior to placebo. A borderline increase in holding exercise volume did not affect maximum voided volume in group E. Monosymptomatic nocturnal enuresis response was significantly lower with all 4 holding exercise volume modulating treatments (7%) compared to alarm therapy (73%).
In the treatment of children with monosymptomatic nocturnal enuresis maximum voided volume can be increased significantly through holding exercises, but not with oxybutynin chloride alone. Compared to controls, increasing maximum voided volume had a minimal effect on monosymptomatic nocturnal enuresis.
我们前瞻性地评估了憋尿训练和/或抗胆碱能药物(氯化奥昔布宁和安慰剂)对增加单纯症状性夜间遗尿症青春期前儿童最大排尿量的疗效。
我们将149名儿童随机分为5组,即接受安慰剂的憋尿训练组(A组)、接受奥昔布宁的憋尿训练组(B组)、单纯安慰剂组(C组)、单纯奥昔布宁组(D组)和警报治疗组(对照组,E组)。最大排尿量是48小时膀胱日记中记录的最大排尿量,憋尿训练量是在液体负荷后每天推迟排尿一次,持续4天所产生的最大尿量。研究药物、憋尿训练程序和警报治疗持续12周。
A组中,憋尿训练联合安慰剂或奥昔布宁分别使憋尿训练量和最大排尿量显著增加25%(p<0.001)和21%(p<0.01);B组中分别增加43%(p<0.001)和41%(p<0.001)。未进行憋尿训练的药物治疗组(C组和D组)的憋尿训练量和最大排尿量未增加,且在这些组中奥昔布宁并不显著优于安慰剂。E组中憋尿训练量的临界增加并未影响最大排尿量。与警报治疗(73%)相比,所有4种调节憋尿训练量的治疗方法对单纯症状性夜间遗尿症的反应率均显著较低(7%)。
在治疗单纯症状性夜间遗尿症儿童时,通过憋尿训练可显著增加最大排尿量,但单独使用氯化奥昔布宁则不能。与对照组相比,增加最大排尿量对单纯症状性夜间遗尿症的影响最小。